TargED: €21.5 Million Series A Extension Raised To Advance Targeted Thrombolytic TGD001
By Amit Chowdhry ● Today at 10:20 PM
TargED Biopharmaceuticals B.V., a clinical-stage biotech company developing targeted treatments for thrombotic diseases, has closed a €21.5 million Series A extension led by BioGeneration Ventures (BGV). Existing investors, including Andera Partners, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures, and Curie Capital, also participated, bringing the company’s total Series A funding to more than €60 million.